Content about Psychiatry

April 9, 2014

According to new survey data recently released by the National Consumers League, one-third of adult Americans still believe that vaccines may be linked to autism in children.

WASHINGTON — According to new survey data recently released by the National Consumers League, one-third of adult Americans still believe that vaccines may be linked to autism in children. According to the survey, 33% of parents of children under the age of 18 and 29% of all adults continue to believe “vaccinations can cause autism.” Scientific studies have clarified that use of vaccines is not linked to autism in children, the NCL noted. 

March 3, 2014

Teva Pharmaceutical Industries announced the launch of Adasuve (loxapine) inhalation powder in a 10-mg dosage. The drug is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults.

JERUSALEM — Teva Pharmaceutical Industries announced the launch of Adasuve (loxapine) inhalation powder in a 10-mg dosage. The drug is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults.

February 27, 2014

A long-term study by UCLA, in collaboration with the University of Aarhus in Denmark, has raised concerns about the use of acetaminophen during pregnancy, UCLA announced earlier this week.

LOS ANGELES — A long-term study by UCLA, in collaboration with the University of Aarhus in Denmark, has raised concerns about the use of acetaminophen during pregnancy, UCLA announced earlier this week.  

In a report in the current online edition of JAMA Pediatrics, researchers from the UCLA Fielding School of Public Health show that taking acetaminophen during pregnancy is associated with a higher risk in children of attention-deficity/hyperactivity disorder and hyperkinetic disorder.  

February 26, 2014

A study released Wednesday by Rhonda Patrick and Bruce Ames of Children's Hospital Oakland Research Institute demonstrated the impact that vitamin D may have on social behavior associated with Autism Spectrum Disorder.

OAKLAND, Calif. — A study released Wednesday by Rhonda Patrick and Bruce Ames of Children's Hospital Oakland Research Institute demonstrated the impact that vitamin D may have on social behavior associated with Autism Spectrum Disorder. 

January 22, 2014

Takeda Pharmaceuticals and Lundbeck announced the availability of Brintellix (vortioxetine), a once-daily oral antidepressant for treatment of major depressive disorder in adults.

DEERFIELD, Ill. — Takeda Pharmaceuticals U.S.A. and Lundbeck on Tuesday announced the availability of Brintellix (vortioxetine) — a once-daily oral antidepressant for treatment of major depressive disorder in adults — in pharmacies across the United States.

“MDD continues to be a challenging condition to manage, and we are proud to make Brintellix available as a new treatment option for people struggling with major depression,” said Douglas Cole, president of Takeda Pharmaceuticals U.S.A.

December 18, 2013

A new study has found a significant increase in the number of high school students who report having abused a common prescription drug for attention deficit hyperactivity disorder, even as abuse of other prescription drugs has decreased or remained low.

NEW YORK — A new study has found a significant increase in the number of high school students who report having abused a common prescription drug for attention deficit hyperactivity disorder, even as abuse of other prescription drugs has decreased or remained low.

December 2, 2013

The Food and Drug Administration has approved a generic version of a drug for schizophrenia and bipolar disorder made by Jubilant Life Sciences, the Indian drug maker said.

NOIDA, India — The Food and Drug Administration has approved a generic version of a drug for schizophrenia and bipolar disorder made by Jubilant Life Sciences, the Indian drug maker said.

Jubilant announced the approval of quetiapine fumarate tablets in the 25-mg strength. The drug is a generic version of AstraZeneca's Seroquel.

Various versions of the drug have annual sales of about $59 million, according to IMS Health.

 

December 2, 2013

Sandoz will market an authorized generic version of an attention deficit hyperactivity disorder drug made by Shire under a contract between the two companies, Shire said Monday.

PHILADELPHIA — Sandoz will market an authorized generic version of an attention deficit hyperactivity disorder drug made by Shire under a contract between the two companies, Shire said Monday.

Shire said Sandoz, the generics division of Swiss drug maker Novartis, would market an authorized generic version of Adderall XR (amphetamine; dextroamphetamine).

November 21, 2013

The Food and Drug Administration has declined to approve an experimental drug for schizophrenia and bipolar disorder developed by Forest Labs and Gedeon Richter, a Hungarian drug company, the two said Thursday.

NEW YORK — The Food and Drug Administration has declined to approve an experimental drug for schizophrenia and bipolar disorder developed by Forest Labs and Gedeon Richter, a Hungarian drug company, the two said Thursday.

The companies said the FDA issued a complete-response letter for cariprazine. The agency issues a complete-response letter when it has finished reviewing an application but issues remain that preclude final approval. In the letter, the FDA acknowledged the drug's efficacy, but wanted more clinical trial data.

November 21, 2013

Teva has introduced a generic version of a drug used to treat attention deficit hyperactivity disorder, the company said Thursday.

NORTH WALES, Pa. – Teva has introduced a generic version of a drug used to treat attention deficit hyperactivity disorder, the company said Thursday.

The drug maker announced the launch of dexmethylphenidate hydrochloride extended-release capsules, a generic version of Novartis' Focalin XR.

Focalin XR has annual sales of about $202 million, according to IMS Health.

 

November 18, 2013

Generic drug maker Mylan has launched its version of a drug for treating attention deficit hyperactivity disorder, the company said Monday.

PITTSBURGH — Generic drug maker Mylan has launched its version of a drug for treating attention deficit hyperactivity disorder, the company said Monday.

Mylan announced the launch of dexmethylphenidate hydrochloride extended-release capsules in the 30-mg strength, a generic version of Novartis' Focalin XR. As the first company to win approval for a generic version of the drug, Mylan has 180 days in which to compete exclusively against Novartis' product.

October 31, 2013

A personalized medicine company said a new study justifies clinical use of pharmacogenomic testing to help predict patients' response to psychiatric medications and improve treatment outcomes.

MASON, Ohio — A personalized medicine company said a new study justifies clinical use of pharmacogenomic testing to help predict patients' response to psychiatric medications and improve treatment outcomes.

October 1, 2013

The Food and Drug Administration has approved a new drug developed by Takeda to treat major depressive disorder, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug developed by Takeda to treat major depressive disorder, the agency said.

The FDA announced the approval of Brintellix (vortioxetine) tablets for treating MDD in adults. The drug will be available in the 5-mg, 10-mg, 15-mg and 20-mg strengths.

August 21, 2013

Rite Aid's philanthropic arm has donated $10,000 to benefit children with autism, according to published reports.

NEW YORK — Rite Aid's philanthropic arm has donated $10,000 to benefit children with autism, according to published reports.

The Macomb County, Mich., Daily reported that the Rite Aid Foundation had made the donation to Sterling Heights, Mich., for use in creating a "Play Place for Autistic Children."

August 1, 2013

Walgreens opened a new training facility here in partnership with Have Dreams, an advocacy group for children with autism, according to a story published Wednesday by Evanston Now.

The training involves setting up displays, working the cash register, stocking and organizing shelves and other skill sets that enable the autistic students to make a contribution to a store’s operations.

EVANSTON, Ill. — Walgreens opened a new training facility here in partnership with Have Dreams, an advocacy group for children with autism, according to a story published Wednesday by Evanston Now

The training involves setting up displays, working the cash register, stocking and organizing shelves and other skill sets that enable the autistic students to make a contribution to a store’s operations.

July 2, 2013

GoodNites, a Kimberly-Clark brand, is helping bed-wetting kids feel confident overnight with a new design that fits more like real underwear.

NEENAH, Wis. — GoodNites, a Kimberly-Clark brand, is helping bed-wetting kids feel confident overnight with a new design that fits more like real underwear.

May 30, 2013

Drugs for attention deficit hyperactivity disorder don't appear to increase children's risk of abusing drugs and alcohol later in life, according to a new study.

NEW YORK — Drugs for attention deficit hyperactivity disorder don't appear to increase children's risk of abusing drugs and alcohol later in life, according to a new study.

May 21, 2013

The Ad Council and Autism Speaks have launched a series of public service announcements encouraging awareness about autism among African-American and Hispanic parents.

NEW YORK — The Ad Council and Autism Speaks have launched a series of public service announcements encouraging awareness about autism among African-American and Hispanic parents.

The groups announced the new series, part of the "Learn the Signs" campaign, which they have launched under a partnership with advertising agency BBDO New York and LatinWorks. Research has indicated that autism is often diagnosed later among children in African-American and Hispanic communities than in others, they said.

April 25, 2013

Actavis can launch a generic version of an attention deficit hyperactivity disorder drug made by Shire next year under an agreement between the two companies announced Thursday.

PARSAPPANY, N.J. — Actavis can launch a generic version of an attention deficit hyperactivity disorder drug made by Shire next year under an agreement between the two companies announced Thursday.

April 2, 2013

More than one-tenth of school-age children and nearly one-fifth of high school boys in the United States have received a diagnosis for attention deficit hyperactivity disorder, according to published reports.

NEW YORK — More than one-tenth of school-age children and nearly one-fifth of high school boys in the United States have received a diagnosis for attention deficit hyperactivity disorder, according to published reports.

The New York Times reported that the dramatic rise in the number of children diagnosed with ADHD over the last decade could lead to concern of over-diagnosis of the condition, as well as overuse of medications to treat it. The Times based its report on an analysis of raw data from the Centers for Disease Control and Prevention.

March 1, 2013

The Food and Drug Administration has approved a once-monthly treatment for schizophrenia.

TOKYO — The Food and Drug Administration has approved a once-monthly treatment for schizophrenia.

Otsuka Pharmaceutical and H. Lundbeck announced the FDA approval of Abilify Maintena (aripiprazole) for extended-release injectable suspension, an intramuscular depot formulation indicated for the treatment of schizophrenia.

The companies described Abilify Maintena as the first dopamine D2 partial agonist approved as a once-monthly injection, contributing to a new treatment option to address the ongoing need for relapse prevention in patients with schizophrenia.

February 11, 2013

Generic drug maker Impax Labs has settled with Shire Labs over an authorized generic version of a Shire drug for treating attention deficit hyperactivity disorder, Impax said.

HAYWARD, Calif. — Generic drug maker Impax Labs has settled with Shire Labs over an authorized generic version of a Shire drug for treating attention deficit hyperactivity disorder, Impax said.

January 23, 2013

The National Advertising Division on Tuesday recommended that Nature’s Answer discontinue a wide range of Internet advertising claims for “Bio-Strath,” including claims that the supplement benefits children with ADD/ADHD, pregnant women, people recovering from cancer treatments, people with dementia and people with diabetes.

NEW YORK — The National Advertising Division on Tuesday recommended that Nature’s Answer discontinue a wide range of Internet advertising claims for “Bio-Strath,” including claims that the supplement benefits children with ADD/ADHD, pregnant women, people recovering from cancer treatments, people with dementia and people with diabetes.

Nature's Answer agreed to comply. 

January 15, 2013

Drug maker Otsuka Pharmaceuticals can keep generic versions of its schizophrenia drug off the market, according to published reports.

NEW YORK — Drug maker Otsuka Pharmaceuticals can keep generic versions of its schizophrenia drug off the market, according to published reports.

Bloomberg reported that the Supreme Court upheld a ruling that allowed Otsuka to block Canadian generic drug maker Apotex from marketing a version of the antipsychotic Abilify (aripiprazole), which Otsuka co-markets with Bristol-Myers Squibb.

January 15, 2013

A maker of drugs for epilepsy has appointed a new executive.

ROCKVILLE, Md. — A maker of drugs for epilepsy has appointed a new executive.

Supernus Pharmaceuticals announced the appointment of Victor Vaughn as SVP sales, a position in which he will be responsible for leading all the company's sales activities.